Based on experience with comprehensive patient involvement, we present data from implementation of portable, programmable infusion pumps (PPP) for home-based chemotherapy administration in patients with acute leukaemia and in lymphoma patients receiving (carmustine, etoposide, cytarabine, melphalan) BEAM regimen. Data from 84 patients, receiving 177 cycles of PPP administered chemotherapy, showed convincing safety with minor equipment errors encountered and with high patient satisfaction. In-hospital days could be reduced with 52% out of a total of 1197 treatment days. Homebased PPP has several advantages from a patient perspective and furthermore frees up in-hospital beds for patients in need of them.
During the past two decades, patient safety aspects in prolonged hospital care have been challenged by non-randomized studies demonstrating that acute leukaemia patients with severe pancytopenia can remain at home by replacing admissions with regular ambulatory visits several times a week (Allan et al, 2001; Savoie et al, 2006; Halim et al, 2007; Eisele et al, 2010; Moller et al, 2010; Saini et al, 2012) . Antibiotic prophylaxis is considered necessary for outpatient treatment with a very low incidence of mortality (Savoie et al, 2006; Eisele et al, 2010; Moller et al, 2010) .
Through a decade, we have developed our outpatient acute leukaemia program as an institutional frontrunner in haematological outpatient management. We have demonstrated the effect of involving patients in the handling of their central venous catheters (CVC), including performing blood sampling and flushing, reducing CVC related infections (Moller et al, 2005) . We have demonstrated the feasibility of outpatient AML treatment and application of lung training techniques to reduce pneumonia (Moller et al, 2010 and latest, a multicentre multimodal patient activation intervention found significant efficacy to mitigate physical declines and improve quality of life during ambulatory waiting time .
So far it has been necessary to give complex chemotherapy regimens in the inpatient setting, due to continuous or multiple daily dosing and in some case the need for complex hydration. In 2012 Sive and colleagues from The University College London Hospital (UCLH) published their experience with a hotel accommodation-based treatment facility for outpatient haemato-oncology care (Sive et al, 2012) . This care delivery allowed patients to receive intensive chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) protocols on a day-care basis with full clinical support, while at the same time staying at a hotel within walking distance from the clinic. Ambulatory infusion pumps were used to provide infusions including hydration for various chemotherapy and antibiotic regimens. Their retrospective analysis demonstrated convincing safety and cost effectiveness (Sive et al, 2012) .
Inspired from UCLH (Sive et al, 2012) , we present preliminary data from an on-going approach by taking chemotherapy provision and outpatient management in acute leukaemia and HSCT to our highest level of patient involvement so far allowing patients to receive complex chemotherapy in their own home without any presence of healthcare professionals.
Patients and methods
From November 2014, we initiated implementation of PPP pumps for AML patients receiving induction, reinduction and consolidation chemotherapy infusions and subsequently also for ALL and lymphoma patients conditioned with the BEAM regimen prior to HSCT. Self-reliant patients with no signs of infection or ongoing bleeding, no need for oxygen supplementation and being haemodynamic stable were discharged with the pre-programmed infusion pump (CADD-Solis VIP Infusion Pump, Smiths Medical UK). This was permanently connected to their CVC, and they carried the pump and chemotherapy in a small bag or backpack (Fig 1) . A team of clinical nurse specialists were responsible of educating patients in the PPP equipment. Patients were individually instructed in how to flush their CVCs, draw blood samples and abort and disconnect an infusion at home, how to react on pump alarming and change of batteries. The patients should contact the clinic if fever (>38Á0 Celsius) or any kind of sudden discomfort occurred. A brief leaflet supplemented the oral guidance and twenty-four-seven telephone contact to the clinic was accessible. Pump instruction material was attached with the pump. The nurse specialist team members certified the staff before they became responsible for pump procedures. Standard supportive care with oral ondansetrone antiemetics was given. Ambulatory visits for PPP patients were scheduled every day to every third day depending on the chemotherapy regimen and the need for blood tests, transfusions and clinical surveillance. Oral antibiotic and anti-fungal prophylaxis was initiated, when neutrophils were <0Á5 bill/l, which was mainly the case during AML induction chemotherapy.
The PPP enables patients to receive chemotherapy in the comfort of their homes via a CVC to the patient (Fig 1) and without health care professionals being present. The pump may be configured to deliver via a variety of profiles: Continuous, intermittent, variable stepped rate, and tapered infusions. A doctor and coordinating nurse specialist established each course specific protocol. The PPP operates with a code to access the infusion settings, which meant that patients were not able to change the settings. Usually only one pump was used for homebased chemotherapy (for AML courses only for cytarabine), but in the BEAM regimen, two pumps were used to administer etoposide and cytarabine. If a problem occurred, the pump alerted with an alarm.
The shift in providing chemotherapy through PPP infusions did not affect dosing or timing of the various chemotherapy regimens. No institutional or ethical approval was required according to the regional ethical committee in this preliminary or subsequent national feasibility study (Ethical J.nr. H-16029560).
Results and discussion
The data from the first 84 patients are given in Table I . We only give data for the days where chemotherapy was administered, not for the following cytopenic phase, which has been previously published 6 . One-hundred and seventy-seven chemotherapy courses representing 1197 infusion days were exclusively performed with the portable, programmable pump irrespective of whether the patient was admitted or received homebased chemotherapy. The patients were equally gendered, half of them were single, the others married or living with a partner (Table I : Panel A). Twenty-five percent of AML induction and ALL PPP infusion days were carried out at home, while the majority were performed as PPP infusions during admission. During AML re-induction and consolidation or HSCT BEAM cycles, home based PPP infusion was more successful with 67 and 82% of the total PPP infusion days being given in the patients' home (Table I: Panel B) .
No serious events occurred, neither chemotherapy extravasation nor incomplete chemotherapy infusions or spills during homebased or hospital-based PPP infusion. Only one incidence of bacteraemia (E. coli) was detected in an inpatient, while the patient was receiving chemotherapy pump infusion (Table I: Panel B) . No patients were acutely admitted from homebased infusion due to infectious complications though four incidences of suspected cytarabine-related fever led to admission. In 2% of infusion days some minor technical and infusion related problems were detected and in half of these, the problem could be solved through telephone guidance, the remaining were fixed in the outpatient clinic (table I: Panel C). The use of the pump rendered all patients more mobile and was well accepted and appreciated by the patients, who stressed the importance of being able to spend time with family and friends, being more physically active, prepare and eat their own food and sleep in their own bed. The most remote patient home was 300 km from the hospital. This 17-year-old ALL patient attended school during a five-day course of a daily one-hour infusion of cytarabine, without visits to the hospital.
Seventy-four % of patients with AML and 51% of ALL could handle their own CVC, thus being able to disconnect their pump and flush their CVC, when the last dose was given.
Prolonged hospital care is indeed being challenged by novel homecare and outpatient management interventions predominantly triggered by prospects of improving quality of life by reducing hospital admission and overall hospital costs (Kern, 2005; Sive et al, 2012) . Our data confirm the experience from UCLH (Sive et al, 2012) and push to a new technology-based development of outpatient acute leukaemia and HSCT management without compromising patient safety. With this setup, our department has been able to reduce the number of in-ward beds with 10%, despite our increasing number of especially elderly patients.
Patients' profound involvement and acceptability is key in this development and the staffs' preparedness to educate and instruct patients and support relatives are an ultimate prerequisite for successful implementation. We have implemented organizational outpatient AML requirements to quickly and effectively manage potential complications (Vaughn et al, 2016 ) by e.g. patients having a 24-h open access to clinics and daily white-board surveillance for patients in the homecare program. However, challenges do exist. A recent qualitative study found that acute leukaemia patients within an outpatient management program expressed a growing desire to understand their long-term care plan, and they were struggling to construct a new sense of identity (Nissim et al, 2014) . In our outpatient AML programme, we systematically schedule the interaction and counselling with the interdisciplinary staff, which seems of utmost importance to support patients' and relatives adaptation irrespective of effective treatment or failure (Jepsen et al, 2016) or their underlying socio-demographic profile (Ostgard et al, 2017) . Likewise, the integration of rehabilitation is necessary to counteract physical decline .
Based on our single institution experience, we have scheduled a national implementation study in six regional centres in Denmark to investigate the feasibility of PPP and homecare based advanced chemotherapy in AML. Moreover, we aim to enlighten the patients' perspectives and will develop a complementary homecare program to enhance patients' physiological, psychological and social adjustments.
We suggest haematology departments to take up homebased chemotherapy administration, which is safe, has several therapeutic advantages from the patients' and family perspectives, and in addition reduces the need for in-hospital beds.
